Ocular Therapeutix (OCUL) has released an update.
Ocular Therapeutix, Inc. has secured a significant investment through a private placement deal, selling over 32 million shares of common stock and nearly 11 million pre-funded warrants to institutional accredited investors, aiming to raise about $325 million. The transaction, involving shares priced at $7.52 and warrants at $7.519 each, is set to close by February 26, 2024. The company is also committed to registering these securities for resale, ensuring investor flexibility. This strategic financial move, facilitated by BofA Securities as the sole placement agent, exemplifies the company’s growth initiatives and commitment to its investors.
For further insights into OCUL stock, check out TipRanks’ Stock Analysis page.
